<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="3968">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on February 08, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04659772</url>
  </required_header>
  <id_info>
    <org_study_id>20-008170</org_study_id>
    <nct_id>NCT04659772</nct_id>
  </id_info>
  <brief_title>A Study to Evaluate Clazakizumab in Patients With Life-threatening COVID-19 Infection</brief_title>
  <official_title>A Randomized Placebo-Controlled Safety And Dose-Finding Study For The Use Of The Il-6 Inhibitor Clazakizumab in Patients With Life-Threatening COVID-19 Infection</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Ayan Sen</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Mayo Clinic</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to investigate the safety of treatment with an investigational&#xD;
      drug called clazakizumab compared to a placebo (inactive substance) in critically ill&#xD;
      patients.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Enrolling by invitation</overall_status>
  <start_date type="Anticipated">December 2020</start_date>
  <completion_date type="Anticipated">December 2020</completion_date>
  <primary_completion_date type="Anticipated">December 2020</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Adverse Events</measure>
    <time_frame>60 days</time_frame>
    <description>Total number of adverse events associated with clazakizumab or placebo</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Covid19</condition>
  <condition>Respiratory Failure</condition>
  <arm_group>
    <arm_group_label>Clazakizumabl Group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo Group</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Clazakizumab</intervention_name>
    <description>The patients will be given a single intravenous dose of clazakizumab 25mg. Patients who fail to achieve the expected decrease in inflammatory markers following the first dose within 48 hours will have the day 1 dose repeated (clazakizumab 25 mg) on or before day 3. Clazakizumab will be administered by intravenous infusion over 30 minutes.</description>
    <arm_group_label>Clazakizumabl Group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>The patients will be given a single intravenous dose of placebo (normal saline, no active drug). Placebo will be administered by intravenous infusion over 30 minutes.</description>
    <arm_group_label>Placebo Group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  â‰¥ 18 years of age.&#xD;
&#xD;
          -  Confirmed COVID-19 disease (by Cobas SARS-CoV-2 real time RT-PCR using nasopharyngeal&#xD;
             swab sample, or equivalent test available to be performed by Mayo Clinic clinical&#xD;
             laboratory). Effort will be made to have the confirmatory test result &lt; 72 hours prior&#xD;
             to enrollment however given overall clinical demand this may not be feasible in all&#xD;
             cases.&#xD;
&#xD;
          -  Respiratory failure manifesting as: Acute Respiratory Distress Syndrome (defined by a&#xD;
             P/F ratio of &lt; 200), OR SpO2 &lt; 90% on 4L (actual or expected given higher O2&#xD;
             requirement) OR increasing O2 requirements over 24 hours, PLUS 2 or more of the&#xD;
             following predictors for severe disease:&#xD;
&#xD;
               -  CRP &gt; 35 mg/L;&#xD;
&#xD;
               -  Ferritin &gt; 500 ng/mL;&#xD;
&#xD;
               -  D-dimer &gt; 1 mcg/L;&#xD;
&#xD;
               -  Neutrophil-Lymphocyte Ratio &gt; 4;&#xD;
&#xD;
               -  LDH &gt; 200 U/L;&#xD;
&#xD;
               -  Increase in troponin in patient w/out known cardiac disease.&#xD;
&#xD;
          -  Has a consent designee willing to provide informed consent on behalf of the patient&#xD;
             (this assumes that a mechanically ventilated patients lacks capacity to consent on&#xD;
             his/her own behalf. Should it be deemed that the patient has capacity to consent,&#xD;
             consent may be obtained from the patient.)&#xD;
&#xD;
          -  Women of childbearing potential must be willing and able to use at least one highly&#xD;
             effective contraceptive method for a period of 5 months following the study drug&#xD;
             administration. In the context of this study, an effective method is defined as those&#xD;
             which result in low failure rate (i.e., less than 1% per year) when used consistently&#xD;
             and correctly such as:&#xD;
&#xD;
               -  Combined (estrogen and progestogen containing) hormonal contraception combined&#xD;
                  (estrogen and progestogen containing) hormonal contraception (oral, intravaginal,&#xD;
                  or transdermal);&#xD;
&#xD;
               -  Progestogen-only hormonal contraception associated with inhibition of ovulation&#xD;
                  (oral, injectable, implantable);&#xD;
&#xD;
               -  Intrauterine device (IUD);&#xD;
&#xD;
               -  Intrauterine hormone-releasing system (IUS);&#xD;
&#xD;
               -  Vasectomized partner;&#xD;
&#xD;
               -  Bilateral tubal occlusion;&#xD;
&#xD;
               -  True abstinence. when this is in line with the preferred and usual lifestyle of&#xD;
                  the subject. Periodic abstinence, such as calendar, ovulation, symptothermal,&#xD;
                  postovulation methods, and withdrawal are not acceptable methods of&#xD;
                  contraception.&#xD;
&#xD;
          -  Men must be willing to use a double-barrier contraception from enrollment until at 5&#xD;
             months after the last dose of study drug, if not abstinent.&#xD;
&#xD;
          -  A subject, or an appropriate representative to the subject, will have the opportunity&#xD;
             to consent with regard to the inclusion criteria above.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  &lt; 18 years of age.&#xD;
&#xD;
          -  Evidence of irreversible injury deemed non-survivable even if the pulmonary failure&#xD;
             recovers (for example severe anoxic brain injury).&#xD;
&#xD;
          -  Known active inflammatory bowel disease.&#xD;
&#xD;
          -  Known active, untreated diverticulitis.&#xD;
&#xD;
          -  Known untreated bacteremia.&#xD;
&#xD;
          -  Pregnancy (the protocol will exclude pregnant subjects given the lack of overall data&#xD;
             on use of clazakizumab in pregnancy however the study team would consider a protocol&#xD;
             revision should more than 3 potential pregnant study subjects be excluded on this&#xD;
             basis).&#xD;
&#xD;
          -  Known hypersensitivity to the clazakizumab.&#xD;
&#xD;
          -  Vulnerable subjects will not be excluded. This study is designed to include any&#xD;
             patients deemed at risk for imminent death, and the opportunity to enroll will not be&#xD;
             withheld provided the subject meets the above inclusion and exclusion criteria.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ayan Sen, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Mayo Clinic</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Mayo Clinic in Arizona</name>
      <address>
        <city>Phoenix</city>
        <state>Arizona</state>
        <zip>85054</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>https://www.mayo.edu/research/clinical-trials</url>
    <description>Mayo Clinic Clinical Trials</description>
  </link>
  <verification_date>December 2020</verification_date>
  <study_first_submitted>December 7, 2020</study_first_submitted>
  <study_first_submitted_qc>December 7, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">December 9, 2020</study_first_posted>
  <last_update_submitted>December 7, 2020</last_update_submitted>
  <last_update_submitted_qc>December 7, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">December 9, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Mayo Clinic</investigator_affiliation>
    <investigator_full_name>Ayan Sen</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Respiratory Insufficiency</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

